



TORRENT PHARMACEUTICALS LIMITED
 Registered Office:
 Torrent House, Off Ashram Road,
 Ahmedabad - 380 009, Gujarat, India.
 Ph. : + 91 79 26599000
 Fax : + 91 79 26582100

TORRENT PHARMACEUTICALS LIMITED

Registered Office:
 Torrent House, Off Ashram Road,
 Ahmedabad - 380 009, Gujarat, India.
 Ph. : + 91 79 26599000
 Fax : + 91 79 26582100

**Extract of Consolidated Financial Results
 for the Quarter ended 30-Jun-2023**

[₹ in crores except per share data]

Particulars	Quarter Ended 30-Jun-2023	Year Ended 31-Mar-2023	Quarter Ended 30-Jun-2022
	Unaudited	Audited	Unaudited
Total Income from operations (net)	2591	9620	2347
Net Profit / (Loss) for the period before tax and exceptional items	531	1847	532
Net Profit / (Loss) for the period before tax and after exceptional items	531	1847	532
Net Profit / (Loss) for the period after tax and exceptional items	378	1245	354
Total Comprehensive Income (after tax)	418	1108	274
Equity Share Capital	169.23	169.23	84.62
Other Equity excluding Revaluation Reserve		6029	
Earnings per share (of ₹ 5/- each) (Refer Note 2)			
Basic	11.18	36.79	10.45
Diluted	11.18	36.79	10.45

Notes :

1 Summary details of stand-alone audited financial results of Torrent Pharmaceuticals Limited :

[₹ in crores]

Particulars	Quarter Ended 30-Jun-2023	Year Ended 31-Mar-2023	Quarter Ended 30-Jun-2022
Net income from operations	2121	7695	1933
Profit before tax	475	1577	494
Profit after tax	323	1052	327
Total Comprehensive Income (after tax)	356	974	279

2 Pursuant to approval given by its shareholders, the Parent Company had allotted 16,92,22,720 equity shares of ₹ 5/- each as fully paid-up bonus equity shares in the ratio of 1 (one) equity share for every 1 (one) existing equity share on 13-Jul-2022. Accordingly, the earnings per share for the quarter ended 30-Jun-2022 has been adjusted and presented in accordance with Ind AS 33, Earnings Per Share.

3 On 14-Oct-2022, the Company acquired 100% shares of Curatio Health Care (I) Private Limited ('Curatio'), including its two subsidiaries. The Board of Directors of the Company, at its meeting held on 21-Dec-2022, had approved the Scheme of Arrangement in the nature of Amalgamation of Curatio with the Company. The scheme was approved by the National Company Law Tribunal ('NCLT'), Ahmedabad Bench on 17-May-2023 with the appointed date of 14-Oct-2022. The financial statements for the year ended 31-Mar-2023 are after giving effect to the amalgamation in books of accounts. Hence, the quarter ended figures, to that extent are not comparable.

4 The above is an extract of the detailed format of Financial Results for the quarter ended 30-Jun-2023 filed with Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the same, along with the notes, are available on www.nscindia.com, www.bseindia.com and on the Company's website www.torrentpharma.com.

Place : Ahmedabad, Gujarat

Date : 7-Aug-2023



CIN: L24230GJ1972PLC002126
Website: www.torrentpharma.com
Email: investorservices@torrentpharma.com

TORRENT PHARMACEUTICALS LIMITED

Registered Office:
Torrent House, Off Ashram Road,
Ahmedabad - 380 009, Gujarat, India.
Ph. : + 91 79 26599000
Fax : + 91 79 26582100

**Extract of Consolidated Financial Results
for the Quarter ended 30-Jun-2023**

[₹ in crores except per share data]

Particulars	Quarter Ended 30-Jun-2023	Year Ended 31-Mar-2023	Quarter Ended 30-Jun-2022
	Unaudited	Audited	Unaudited
Total Income from operations (net)	2591	9620	2347
Net Profit / (Loss) for the period before tax and exceptional items	531	1847	532
Net Profit / (Loss) for the period before tax and after exceptional items	531	1847	532
Net Profit / (Loss) for the period after tax and exceptional items	378	1245	354
Total Comprehensive Income (after tax)	418	1108	274
Equity Share Capital	169.23	169.23	84.62
Other Equity excluding Revaluation Reserve		6029	
Earnings per share (of ₹ 5/- each) (Refer Note 2)			
Basic	11.18	36.79	10.45
Diluted	11.18	36.79	10.45

Notes :

1 Summary details of stand-alone audited financial results of Torrent Pharmaceuticals Limited:

[₹ in crores]

Particulars	Quarter Ended 30-Jun-2023	Year Ended 31-Mar-2023	Quarter Ended 30-Jun-2022
Net income from operations	2121	7695	1933
Profit before tax	475	1577	494
Profit after tax	323	1052	327
Total Comprehensive Income (after tax)	356	974	279

2 Pursuant to approval given by its shareholders, the Parent Company had allotted 16,92,22,720 equity shares of ₹ 5/- each as fully paid-up bonus equity shares in the ratio of 1 (one) equity share for every 1 (one) existing equity share on 13-Jul-2022. Accordingly, the earnings per share for the quarter ended 30-Jun-2022 has been adjusted and presented in accordance with Ind AS 33, Earnings Per Share.

3 On 14-Oct-2022, the Company acquired 100% shares of Curatio Health Care (I) Private Limited ('Curatio'), including its two subsidiaries. The Board of Directors of the Company, at its meeting held on 21-Dec-2022, had approved the Scheme of Arrangement in the nature of Amalgamation of Curatio with the Company. The scheme was approved by the National Company Law Tribunal ('NCLT'), Ahmedabad Bench on 17-May-2023 with the appointed date of 14-Oct-2022. The financial statements for the year ended 31-Mar-2023 are after giving effect to the amalgamation in books of accounts. Hence, the quarter ended figures, to that extent are not comparable.

4 The above is an extract of the detailed format of Financial Results for the quarter ended 30-Jun-2023 filed with Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the same, along with the notes, are available on www.nscindia.com, www.bscindia.com and on the Company's website www.torrentpharma.com.

Place : Ahmedabad, Gujarat

Date : 7-Aug-2023